April 24, 2024 | HighField Bio Press Release

HighField Biopharmaceuticals Announces Two Abstracts Accepted for the 2024 ASCO Annual Meeting

The company is developing next generation lipid-based structures that kill cancer cells and expose cancer to the immune system

HANGZHOU, China –April 24, 2024– HighField Biopharmaceuticals, a clinical stage immuno-oncology company using lipid-based therapeutics to treat cancer, announced today that two HighField abstracts have been accepted with one poster presentation at the American Society of Clinical Oncology (ASCO) annual meeting May 31-June 4, 2024, in Chicago, IL.

“The ASCO meeting is an important opportunity to share our unique lipid-based technology with other clinical investigators,” said Yuhong Xu, Ph.D., Founder and CEO of HighField. “Our lipid-based structures represent a new generation of therapeutics targeting the tumor microenvironment for a broad range of cancers.”

The abstracts reflect Phase 1 clinical trials of two kinds of lipid-based therapeutics. HFK1 is a drug encapsulated immunoliposome containing doxorubicin for patients with advanced refractory solid tumors having HER2 low and HER2+ expression. HER2 expressing solid tumors include breast, bladder, pancreatic, ovarian, stomach, colon, prostate, lung, uterus and cervix cancers. HF1K16 is a drug encapsulated immune modulating liposome containing all-trans retinoic acid (ATRA) for patients with recurrent and refractory glioma.

HFK1 Poster Presentation
Abstract ID: 3035
Title: The design, preclinical study and Phase 1 dose escalation of a HER2 targeted immunoliposome (HF-K1) for HER2 low solid tumor treatment.
Presenter: Dr. Yuhong Xu, Ph.D.
Presenter Date: Saturday, June 1, 2024 (9am -12pm)

HF1K16 Abstract for Publication
Abstract ID.: e14030
Title: Exploratory phase 1 study of HF1K16 for the treatment of patients with refractory/recurrent advanced glioma: preliminary efficacy and mechanism as a monotherapy.

About HighField Biopharmaceuticals

HighField is a clinical stage immuno-oncology company focused on novel applications of liposome constructs to disrupt existing immuno-oncology technologies. The company also has a research and development center and a GMP-compliant production facility. HighField’s lead clinical development program is HF1K16, a drug encapsulated immune modulating liposome containing all-trans retinoic acid targeting myeloid-derived suppressor cells for treatment of solid tumors. The company’s pipeline also includes drug encapsulated immunoliposomes for solid tumor cancers. For more information visit https://highfield.bio.


Media Contact:
Dan Eramian
Opus Biotech Communications

Business Development Contact:
Donald Wyatt
HighField Biopharmaceuticals